Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolimidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYN known ✓ | P07948 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042256 | 0.82 | ALDH1A1 (0.61) | LYNALDH1A1HTTMEN1KMT2A | |
| SCHEMBL456868 | 0.80 | ALDH1A1 (0.72) | LYNALDH1A1HTTMEN1KMT2A | |
| SCHEMBL29398372 | 0.80 | ALDH1A1 (0.72) | LYNALDH1A1HTTMEN1KMT2A | |
| SCHEMBL29746015 | 0.80 | ALDH1A1 (0.72) | LYNALDH1A1HTTMEN1KMT2A | |
| SCHEMBL5042253 | 0.79 | LYN (0.54) | LYNALDH1A1HTTMEN1KMT2A | |
| SCHEMBL8736450 | 0.79 | LYN (0.60) | LYNALDH1A1HTTMEN1KMT2A | |
| SCHEMBL29377828 | 0.78 | ALDH1A1 (0.69) | LYNALDH1A1HTTMEN1KMT2A | |
| SCHEMBL1688852 | 0.78 | ALDH1A1 (0.69) | LYNALDH1A1HTTMEN1KMT2A | |
| SCHEMBL29851471 | 0.78 | ALDH1A1 (0.55) | LYNALDH1A1HTTMEN1KMT2A | |
| SCHEMBL6061453 | 0.77 | ACHE (0.64) | LYNALDH1A1HTTKMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3737669-B1 | METHOD FOR PREPARING TOLIMIDONE ON LARGE SCALE | BUKWANG PHARMACEUTICAL CO LTD (KR) | 2023-08-30 | — | — | EP | disclosed |
| US-11254645-B2 | Method for preparing tolimidone on large scale | BUKWANG PHARMACEUTICAL CO., LTD. (KR) | 2022-02-22 | — | — | US | disclosed |
| US-20210061772-A1 | METHOD FOR PREPARING TOLIMIDONE ON LARGE SCALE | BUKWANG PHARMACEUTICAL CO., LTD. (KR) | 2021-03-04 | — | — | US | disclosed |
| WO-2019139185-A1 | METHOD FOR PREPARING TOLIMIDONE ON LARGE SCALE | BUKWANG PHARMACEUTICAL CO., LTD. (KR) | 2019-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254645-B2 | Method for preparing tolimidone on large scale | ACR, TES, RPLP0 | LYN 889/4885ALDH1A1 1535/4885HTT 475/4885 |
| US-20210061772-A1 | METHOD FOR PREPARING TOLIMIDONE ON LARGE SCALE | ACR, TES, RPLP0 | LYN 889/4885ALDH1A1 1535/4885HTT 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.